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Binge-eating disorder is the most common eating disorder. Various neuropeptides play important roles in the regulation of feeding
behavior, including relaxin-3 (RLN3), which stimulates food intake in rats through the activation of the relaxin-family peptide-3 recep-
tor (RXFP3). Here we demonstrate that a likely mechanism underlying the orexigenic action of RLN3 is RXFP3-mediated inhibition
of oxytocin- and arginine-vasopressin-synthesizing paraventricular nucleus (PVN) magnocellular neurosecretory cells. Moreover, we
reveal that, in male and female rats, this action depends on M-like potassium conductance. Notably, higher intra- and peri-PVN
RLN3 fiber densities were observed in females, which may constitute an anatomic substrate for observed sex differences in binge-eat-
ing disorder. Finally, in a model of binge-eating in female rats, RXFP3 blockade within the PVN prevented binge-eating behavior.
These data demonstrate a direct RLN3/RXFP3 action in the PVN of male and female rats, identify the associated ionic mechanisms,
and reveal that hypothalamic RLN3/RXFP3 signaling regulates binge-eating behavior.
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Significance Statement
Binge-eating disorder is the most common eating disorder worldwide, affecting women twice as frequently as men. Various neuro-
peptides play important roles in the regulation of feeding behavior, including relaxin-3, which acts via the relaxin-family peptide-3
receptor (RXFP3). Using a model of binge-eating, we demonstrated that relaxin-3/RXFP3 signaling in the hypothalamic paraventric-
ular nucleus (PVN) is necessary for the expression of binge-eating behavior in female rats. Moreover, we elucidated the neuronal
mechanism of RLN3/RXFP3 signaling in PVN in male and female rats and characterized sex differences in the RLN3 innervation of
the PVN. These findings increase our understanding of the brain circuits and neurotransmitters involved in binge-eating disorder
pathology and identify RXFP3 as a therapeutic target for binge-like eating disorders.
Introduction
Relaxin-3 (RLN3) is a neuropeptide expressed mainly in neurons
of the brainstem nucleus incertus (NI). Smaller assemblies of
RLN3 neurons are scattered within the pontine raphe nucleus
(PnR), an area dorsal to the substantia nigra (dSN), and in the
medial/ventral periaqueductal gray (PAG). The cognate metabo-
tropic receptor for RLN3, relaxin-family peptide 3 receptor
(RXFP3) couples to Gi/o-proteins and is widely expressed in the
CNS (for review, see Bathgate et al., 2013).
RLN3/RXFP3 signaling plays an important role in the control
of food intake, arousal and motivation, contextual and spatial
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memory, neuroendocrine processes, and stress responses (for
review, see Ganella et al., 2012, 2013b; Ma and Gundlach, 2015;
Blasiak et al., 2017; Calvez et al., 2017; Ma et al., 2017).
Moreover, a high sensitivity of RLN3-synthesizing neurons to
stress-related factors positions the RLN3/RXFP3 system at the
interface between environmental demands and these physiologi-
cal processes (Tanaka et al., 2005; Ma et al., 2013). The first
reported effect of central administration of RLN3 was hyperpha-
gia in satiated, male rats (McGowan et al., 2005). Since then, sev-
eral studies have further characterized this orexigenic action
(McGowan et al., 2005, 2006, 2007; Ganella et al., 2013a; Kania et
al., 2017). Moreover, expression of RLN3 mRNA in the NI is ele-
vated in rats with diet-induced obesity (Lenglos et al., 2014).
RLN3 peptide signaling is also involved in stress-induced binge-
eating (BE), as RLN3 mRNA is elevated in binging female rats,
and intracerebroventricular injection of an RXFP3 antagonist
prevents the occurrence of binge-like eating (Lenglos et al., 2013;
Calvez et al., 2016b). Notably, BE disorder (BED) is the most
prevalent eating disorder worldwide (between 0.2% and 4.7% of
the adult population), with women affected twice as frequently
as men (Kessler et al., 2013). BED is characterized by recurrent
BE episodes associated with a sense of lack of control over eating,
and is often accompanied by overweight or obesity (American
Psychiatric Association, 2013; for review, see Hutson et al., 2018;
Novelle and Diéguez, 2018).
Magnocellular neurosecretory cells (MNCs) of the hypothala-
mic paraventricular nucleus (PVN) have been identified as an im-
portant site of the orexinergic action of RLN3 (McGowan et al.,
2005, 2006; Ganella et al., 2013a). MNCs in the PVN largely con-
tribute to the pool of oxytocin (OXT) and arginine-vasopressin
(AVP) hormones in mammals; peptides involved in a plethora of
homeostatic processes, including food intake (for review, see
Gimpl and Fahrenholz, 2001; Koshimizu et al., 2012). Among
many extrinsic modulatory inputs controlling MNCs, our recent
studies described a strong inhibitory influence of RXP3 activation
on the activity of PVN MNCs in male Wistar rats (Kania et al.,
2017) and revealed that chronic activation of PVN RXFP3 led to
increased body weight gain, accompanied by reduced expression
of anorexigenic OXT and AVP mRNA (Ganella et al., 2013a).
The physiological roles of both OXT and AVP are sex-specific
(de Vries, 2008; Dumais and Veenema, 2016). At the same time,
PVN RXFP3 mRNA levels are higher in female than in male rats,
and some RLN3 actions are sex-dependent (for review, see Calvez
et al., 2017). Intracerebroventricular administration of RLN3
caused stronger hyperphagia in female than in male rats, and
when delivered chronically it led to more profound body weight
gain in females (Calvez et al., 2015, 2016a; Lenglos et al., 2015).
Despite the well-described role of RLN3/RXFP3 signaling in
food intake control, the neuronal and ionic mechanisms underly-
ing RXFP3 action, and its role in stress-related abnormalities in
food intake, remain poorly understood. Furthermore, the neuro-
nal basis of the sexual diversity in the influence of RLN3/RXFP3
signaling on food intake is not known. Therefore, we investigated
the ionic mechanism underlying the RXFP3-induced inhibition
of PVN MNCs, and the influence of RXFP3 activation on MNC
synaptic inputs in male and female rats. We also characterized
the RLN3 innervation of the PVN area in rats of both sexes.
Finally, we assessed PVN RXFP3 signaling involvement in the
modulation of BE behavior in female rats.
Materials and Methods
Ethical approval. All procedures were conducted in accordance with
the directive 2010/63/EU of the European Parliament and of the Council
of September 22, 2010 on the protection of animals used for scientific
purposes. Procedures in immunostaining, neural tract-tracing, patch-
clamp, and scRT-PCR experiments were additionally conducted in ac-
cordance with the Polish Act on the Protection of Animals Used for
Scientific or Educational Purposes of January 15, 2015 and approved by
the first and second Local Institutional Animal Care and Use Committee
(Krakow, Poland). All efforts were made to minimize suffering and to
reduce the number of animals used.
Animals and reagents. Male and female Sprague Dawley rats used in
immunostaining, neural tract-tracing, patch-clamp, and scRT-PCR
experiments were bred and housed in a conventional animal facility. Rats
were kept in plastic cages linedwithwoodenbedding, in constant environ-
mental conditions (216 2°C), maintained on 12-12 light-dark cycle (light
on at 08:00 h) with ad libitum access to fresh water and standard labora-
tory rodent chow. From 4 weeks of age, rats were separated from dams
and kept in same sex cages, until use in experiments. Rats between 6 and
8weeks old were used for patch-clamp and scRT-PCR experiments,
whereas 3-month-old rats were used for neural tract-tracing studies and
4-month-old ratswere used for immunostaining experiments.
For the behavioral experiments, young, female Sprague Dawley rats
were purchased from Charles River (Italy) and housed in the animal fa-
cility in individual cages for 4 weeks before the experiment and kept in
constant environmental conditions (216 2°C), maintained on 12-12
light-dark cycle (light on at 09:00 h) with ad libitum access to fresh water
and standard food pellets (4RF18).
All reagents for PBS solution, ACSF, and intrapipette solution were
purchased from Sigma Millipore, apart from some biocytin batches pur-
chased from Tocris Bioscience (catalog #3349).
Electrophysiology reagent suppliers were as follows: TTX citrate
(Abcam, catalog #ab120055 or Tocris Bioscience, catalog #1069), DL-
AP5 (Tocris Bioscience, catalog #0105), CNQX (Tocris Bioscience, cata-
log #1045), bicuculline methiodide (Sigma Millipore, catalog #14343),
cadmium chloride hydrate (Sigma Millipore, catalog #529575), tetraeth-
ylammonium-chloride (Tocris Bioscience, catalog #3068), 4-aminopiri-
dine (Tocris Bioscience, catalog #0940), and XE991 dihydrochloride
(Abcam, catalog #ab120089).
Peptides used were as follows: RLN3 (Phoenix Pharmaceuticals, cata-
log #035-36A), RXFP3 agonist, RXFP3-A2 {[R3A(11-24,C15!A)B]},
synthesized using solid-phase peptide synthesis and purified using
reverse-phase HPLC (Florey Institute of Neuroscience and Mental
Health, Victoria, Australia), and the RXFP3 antagonist, R3 (B1-22)R
(kindly provided by K.J. Rosengren, University of Queensland). All pep-
tides were dissolved in deionized water, aliquoted, and stored at 20°C,
except RLN3, which was dissolved in 10% acetonitrile solution in deion-
ized water and kept in low protein-binding tubes to prevent peptide
adsorption to the plastic surface during storage at20°C.
Immunostaining reagent suppliers were as follows: formaldehyde
36%–38% solution (POCH, catalog #432173111), Triton X-100 (Sigma
Millipore, catalog #11332481001), normal donkey serum (NDS, Abcam,
catalog #ab7475), avidin-fluorescein conjugate (Sigma Millipore, catalog
#94091), mouse anti-OXT antibody (Abcam, catalog #ab78364; or
Merck Millipore, catalog #MAB5296), rabbit anti-vasopressin antibody
(Abcam, catalog #ab39363), anti-mouse AlexaFluor-647-conjugated
antibody (Jackson ImmunoResearch Laboratories, catalog #715-606-
150), anti-rabbit Cy3-conjugated antibody (catalog #711-165-152),
ImmPRESS HRP anti-mouse IgG polymer detection kit (Vector
Laboratories, catalog #MP-7402), DAB peroxidase substrate kit
(Vector Laboratories, catalog #MP-4100), and Fluoroshield with
DAPI (Sigma Millipore, catalog #F6057). The mouse RLN3 antibody
was prepared in-house (Florey Institute of Neuroscience and Mental
Health) using a monoclonal cell line originally supplied by the
International Patent Organism Depository National Institute of
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Advanced Industrial Science and Technology (Tsukuba, Ibaraki,
Japan). Primary antibodies and NDS were aliquoted and stored at
20°C; secondary antibodies were aliquoted and stored at 80°C.
RT-PCR reagent suppliers were as follows: RNase inhibitor (Thermo
Fisher Scientific, catalog #EO0381), Maxima H Minus cDNA Synthesis
Master Mix, with dsDNase (Thermo Fisher Scientific, catalog #M1681),
dNTPs (Thermo Fisher Scientific, catalog #R0192), primers (Genomed),
and Taq DNA polymerase (Thermo Fisher Scientific, catalog #EP0401).
Whole-cell recording: tissue preparation, data acquisition and analy-
sis. Whole-cell recordings were performed as described previously
(Blasiak et al., 2015; Kastman et al., 2016; Kania et al., 2017). In brief,
male and female Sprague Dawley rats (6–8weeks old) were anesthetized
with isoflurane (AErrane, Baxter) and decapitated between 02:00 and
03:00 ZT. Brains were collected in ice-cold, low-sodium, high-magne-
sium ACSF, containing the following (in mM): 185 sucrose, 25 NaHCO3,
3 KCl, 1.2 NaH2PO4, 2 CaCl2, 10 MgSO4, and 10 glucose, pH 7.4 (osmo-
lality 290-300 mOsmol kg1) and cut into 250-mm-thick coronal sections
on a VT 1000S vibrating microtome (Leica Instruments). Sections con-
taining the PVN were bisected along the third ventricle and transferred
to an incubation chamber containing carbogenated, warm (32°C) ACSF,
containing the following (in mM): 118 NaCl, 25 NaHCO3, 3 KCl, 1.2
NaH2PO4, 2 CaCl2, 1.3 MgSO4, and 10 glucose, pH 7.4 (osmolality 290–
300 mOsmol kg1). After a recovery period (90-120min), slices were
transferred to a recording chamber, where the tissue was perfused (2 ml
min1) with carbogenated, warm (32°C) ACSF of the same composition.
Recording micropipettes were fabricated from borosilicate glass
capillaries (5-7 MX; Sutter Instruments) using a horizontal puller (Sutter
Instruments) and filled with a solution containing the following (in mM):
145 potassium gluconate, 2 MgCl2, 4 Na2ATP, 0.4 Na3GTP, 5 EGTA,
10 HEPES, pH 7.3 (osmolality 290-300 mOsmol kg1) and biocytin
(0.05%, for subsequent immunofluorescent identification of recorded
neurons). The calculated liquid junction potential for thisACSF and intra-
pipette solutionwas 15mV; and this valuewas subtracted fromthedata.
PVN neurons were localized and approached using an Axio Scope
FS2 and Examiner D1 microscope (Carl Zeiss) equipped with video-
enhanced infrared differential interference contrast. Cell-attached and
whole-cell configurations were obtained under visual control using a
negative pressure delivered by an ez-gSEAL pressure controller
(NeoBiosystem) or mouth suction. SEC 05LX amplifiers (NPI), Micro
1401 mk II (Cambridge Electronic Design) converters and Signal and
Spike2 software (Cambridge Electronic Design) were used for signal re-
cording and data acquisition. Recorded signal was low-pass filtered at
3 kHz and digitized at 20 kHz.
PVN neurons were identified based on their unique electrophysio-
logical properties. Type I neurons (putative MNCs) were identified by
the presence of the transient outward rectification underlined by robust
A-type potassium current (Luther and Tasker, 2000). Activation of this
current results in a delay to the first action potential when an MNC is
depolarized from the hyperpolarized membrane state (100mV). Type
II cells (putative parvocellular neurons) lack the delay and display low-
threshold spikes caused by T-type calcium current (Luther and Tasker,
2000). Only Type I neurons were the subject of the present study, and
only those with stable input resistance throughout recording, monitored
based on the voltage or current responses to hyperpolarizing current or
voltage steps (applied every 30 or 60 s), were included in the final analy-
sis. According to these criteria, 244 MNCs (123 from male and 121 from
female brains) recorded in the slices obtained from 117 young, adult
Sprague Dawley rats (59 males and 58 females) were included in the cur-
rent study. Only one neuron per slice was subjected to peptide adminis-
tration in these experiments. All peptides and drugs were applied via
bath perfusion system.
Current-clamp recordings (zero holding current) aimed at investigat-
ing MNC sensitivity to RXFP3 activation were performed in normal
ACSF followed by ACSF containing TTX (0.5mM, to block action poten-
tial generation) and antagonists of ionotropic glutamate and GABA
receptors (10 mM CNQX, 50 mM DL-AP5, and 20 mM bicuculline, respec-
tively). Voltage-clamp recordings (command potential 50mV) aimed
at investigating MNC sensitivity to RXFP3 activation and the ionic
mechanism of RXFP3-mediated inhibition were performed in ACSF
containing TTX, CNQX, DL-AP5, and bicuculline and additional
compounds: Cd21 (200 mM), tetraethylammonium-chloride (10 mM),
4-aminopiridine (100mM), and XE991 (10 mM and 50 mM). In a subset of
experiments, ACSF with increased [K1] (final concentration: 21.6 mM,
with a simultaneous decrease in NaCl concentration) was used. Voltage-
clamp recordings (command potential 50mV) aimed at investigating
the influence of RXFP3 activation on spontaneous and miniature synap-
tic currents were performed in normal ACSF and ACSF-containing
TTX, respectively. Calculated reversal potential for Cl currents in our
patch-clamp recordings equaled 90.51mV; therefore, at the given
command potential, outward events represented IPSCs, whereas inward
events represented EPSCs. The nature of postsynaptic currents was veri-
fied using glutamate (CNQX 10 mM, DL-AP5 50 mM) and GABA (bicu-
culline 20mM) receptor antagonists.
After recording, slices underwent immunofluorescent staining to
examine neurochemical content of recorded neurons. The procedure
was conducted according to described protocols (Blasiak et al., 2015;
Kastman et al., 2016; Kania et al., 2017). Briefly, slices were fixed over-
night with 4% formaldehyde at 4°C. Fixed free-floating sections were
blocked and permeabilized (10% NDS, 0.6% Triton X-100 in PBS) at 4°C
overnight and incubated with a primary antibody solution as follows:
mouse anti-OXT (1:10 000 or 1:5000 depending on the antibody batch),
rabbit anti-vasopressin (1:500 or 5000 depending on the antibody batch),
avidin-fluorescein conjugate (1:200), 2% NDS, 0.3% Triton X-100 in
PBS, for 72 h at 4°C. Following incubation with secondary antibodies:
donkey anti-mouse AlexaFluor-647 (1:400), donkey anti-rabbit Cy3
(1:400), 2% NDS in PBS for 24 h at 4°C, sections were coverslipped with
Fluoroshield containing DAPI and imaged with a fluorescence micro-
scope (Axio Imager M2, Carl Zeiss).
Single-cell RT-PCR (sc-RT-PCR). PVN-containing brains sections
from 6 Sprague Dawley rats (3 males and 3 females) were prepared simi-
larly to the protocol characterized above, and MNCs were recorded
using described whole-cell protocols with 1-2 MX recording micropip-
ettes. After electrophysiological verification of the cell type, MNCs were
voltage-clamped at 50mV, and the cytoplasmic content was aspired
into the recording micropipette while whole-cell current was being
monitored. The aspiration lasted until the interruption of the whole-cell
configuration. The cytoplasmic samples were deposited in plastic tubes
containing 0.5ml of RNase inhibitor and stored at 80°C until the PCR
was conducted to investigate the expression of the following mRNA spe-
cies: RXFP3, KCNQ2-5, and GAPDH.
DNase treatment and reverse transcription were performed using
Maxima H Minus cDNA Synthesis Master Mix, with dsDNase (Thermo
Fisher Scientific) according to the manufacturer’s instructions. After
reverse transcription, the cDNA for GAPDH, RXFP3, and KCNQ2-5
was amplified in a seminested multiplex PCR. First-round PCR amplifi-
cation was performed in a 50ml volume containing 10 mM Tris-HCl, pH
8.8, 50 mM KCl, 0.08% (v/v) Nonident P40, 2 mM MgCl2, 250 mM
dNTPs, 40 nM primers, 6ml cDNA, and 1.25 U Taq DNA polymerase.
Second-round PCRs were performed separately for each gene in a 25ml
volume; 4ml of the first-round PCR product was used and the concen-
tration of primers was increased by 10. Detailed sequences of primers
used in PCRs are summarized in Table 1. All PCRs were run in a
T100TM Thermal Cycler (Bio-Rad) for 34 cycles of 30 s denaturation at
95°C, 1min annealing at 52°C and 90 s elongation at 72°C, preceded
with 3min denaturation at 95°C and followed by a final elongation pe-
riod of 5min at 72°C; 25ml of second-round PCR products was sepa-
rated on Midori Green (Nippon Genetics) stained 2% agarose gels and
visualized by UV trans-illumination. Predicted sizes of the PCR ampli-
cons were as follows: GAPDH, 284 bp; RXFP3, 422 bp; KCNQ2, 216 bp;
KCNQ3, 253 bp; KCNQ4, 322 bp; and KCNQ5, 484 bp. All experiments
included a control tube, in which RevertAid Reverse Transcriptase was
omitted in the reverse transcription negative test.
Neural tract-tracing: surgeries, tissue preparation, and immunostain-
ing. Injections of neuronal tracer were performed according to described
procedures (Blasiak et al., 2015; Kania et al., 2017). In brief, male (n=5)
and female (n=8) Sprague Dawley rats (10weeks old) were anesthetized
with isoflurane in an induction chamber, mounted into a small animal
stereotaxic system (SAS-4100; ASI Instruments) with a rat gas anesth-
esia mask (Stoelting) and maintained under deep anesthesia with 3%
isoflurane (v/v mixture with air). Retrograde tracers (FluoroGreen,
5364 • J. Neurosci., July 8, 2020 • 40(28):5362–5375 Kania et al. · RLN3/RXFP3 Signaling in the PVN
FluoroPink, 40 nl, Tombow Pencil) were injected bilaterally into the
PVN (stereotaxic coordinates: AP1.7 mm [males]1.5 mm [females],
ML 0.4 mm and DV 7.8 mm from bregma) (Paxinos and Watson,
2007), using glass microinjection pipettes (50mm tip), pulled from boro-
silicate glass capillaries on a vertical puller (Narishige) connected to 1ml
Hamilton syringe (Hamilton). After 9 d of recovery, rats were again
anesthetized with isoflurane for colchicine injection to improve the
detection of somatic RLN3 immunoreactivity. Colchicine solution
(0.5mg in 5ml of 0.9% NaCl made on the day of injection, Sigma
Millipore, catalog #C9754) was injected unilaterally into the lateral cere-
bral ventricle (stereotaxic coordinates: AP 0.7 mm, ML 1.8 mm, and
DV4.0 mm from bregma) using glass microinjection pipettes. After 24
h, rats were anesthetized with pentobarbital (240mg/kg, i.p., Morbital,
Biowet) and killed by transcardial perfusion with 200 ml of saline fol-
lowed by 200 ml of 4% formaldehyde in PBS (made fresh from 38% solu-
tion). Brains were postfixed in 4% formaldehyde in PBS overnight at 4°C
and cut into coronal sections on a VT1000S vibrating microtome (Leica
Instruments). Brain sections (100mm thick) containing injection sites
were mounted, coverslipped using glycerin, and imaged with a fluores-
cent microscope (Axio Imager M2, Carl Zeiss). Injection sites were veri-
fied and reconstructed using CorelDraw software according to the rat
brain atlas (Paxinos andWatson, 2007).
Every third section (50mm) containing brain regions synthesizing
RLN3 (PAG, dSN, PnR, and NI) was immunostained to visualize RLN3-
synthesizing neurons according to described protocols (Kania et al.,
2017). Briefly, free-floating sections were incubated with 10% NDS, 0.3%
Triton-X 100 in PBS for 1 h at room temperature. After blocking and
permeabilization slices were incubated with a primary antibody solution
(mouse anti-RLN3, 1:50, 2% NDS, 0.3% Triton X-100 in PBS for 72 h at
4°C) and subsequently with a secondary antibody solution (donkey anti-
mouse AlexaFluor-647, 1:400, 2% NDS in PBS for 24 h at 4°C). Finally,
sections were mounted and coverslipped with Fluoroshield-containing
DAPI, and imaged with a fluorescence microscope (Axio Imager M2,
Carl Zeiss) and LSM710 confocal laser microscope on Axio Observer Z1
(Carl Zeiss). RLN3-immunoreactive (-ir) neurons containing FluoroPink
or FluoroGreen were counted using ZEN 2.1 software and multiplied
(3) to estimate the total cell number.
RLN3 fiber immunostaining: perfusion and fixed tissue preparation.
In a separate set of immunostaining experiments, male (n= 4) and
female (n= 8) Sprague Dawley rats (4months old) were anesthetized
with pentobarbital (240mg/kg, i.p.), killed by transcardial perfusion, and
their brains were processed as described above (see Neural tract-tracing:
surgeries, tissue preparation, and immunostaining).
For visualization of RLN3-positive fibers in the hypothalamus, every
third 40mm coronal section containing PVN was slide-mounted and
underwent immunohistochemical staining using a Vector ImmPRESS
kit according to the manufacturer’s protocol. All procedures were con-
ducted in a humidity chamber on slide-mounted sections at room tem-
perature. Briefly, after blocking the endogenous peroxidase activity
(0.3% H2O2 in PBS for 10min), sections were permeabilized (0.025%
Triton X-100 in PBS for 2 5min) and blocked (2.5% normal horse se-
rum for 20min). Subsequently, sections were incubated with a primary
antibody solution (mouse anti-RLN3, 1:50, 0.3% Triton X-100 in PBS
for 90min) followed by anti-mouse secondary antibody conjugated with
HRP polymer (for 30min). Finally, sections were incubated with a per-
oxidase substrate solution (DAB for 10min), rinsed in tap water and
coverslipped with glycerin. Stained sections were imaged using a light
microscope (Axio Imager M2, Carl Zeiss) with a 20/0.5 Plan Neofluar
objective and an AxioCamMR R3 digital camera.
Binge eating experiments: cannula implantation and behavioral
testing. Female Sprague Dawley rats (n=20, ;260 g at the beginning of
the study) were subjected to bilateral intracranial cannulation surgery, to
allow intra-PVN microinjections. Rats were anesthetized with an intra-
muscular injection of tiletamine chlorahydrate (200mg/kg) and zolaze-
pam chlorahydrate (200mg/kg; Virbac), together with a subcutaneous
injection of anti-inflammatory meloxicam (1.5mg/kg) and mounted into a
small animal stereotaxic instrument (model 902; David Kopf Instruments).
Stainless-steel cannulae (22 gauge; Unimed) were implanted bilaterally and
mounted to the skull with stainless-steel screws and dental cement, using
the following stereotaxic coordinates: AP 1.6 mm, ML 61.8 mm, a 10°,
DV 7.0 mm from bregma (Paxinos and Watson, 2007). A stainless-steel
dummy cannula was placed inside the guide cannula at the end of the sur-
gery. After 14d of postsurgical recovery, the BEmodel procedure began.
Microinjections were made using stainless-steel injectors (Unimed)
connected with polyethylene-10 tubing to the 10ml Hamilton syringes
(tips of injectors were protruding from the guide cannulae by 1.5 mm).
The selective RXFP3 antagonist, R3(B1-22)R was diluted (1mg/0.5ml) in
ACSF (in mM as follows: 147 NaCl, 4 KCl, 0.85 MgCl2, 2.3 CaCl2); 0.5ml
of vehicle (ACSF) or R3(B1-22)R solution was manually injected into
each side of the PVN (;0.5ml/min). The injectors were left in the guide
cannulae for;30 s after the infusion.
A BE protocol was conducted as described previously (Cifani et al.,
2009; Micioni Di Bonaventura et al., 2012, 2013; Pucci et al., 2016;
Alboni et al., 2017). Briefly, rats were divided into two weight-matched
groups: one exposed to three consecutive 8-d-long cycles of caloric
restriction and refeeding (access to 66% of normally consumed chow,
days 1-4 of each cycle, followed by ad libitum access to chow, days 5–8
of each cycle); while at the same time, a second group of rats with ad
libitum access to chow throughout the entire period (24 d). Additionally,
on days 5–6 and 13–14 (four exposures), rats from both groups were
given access to highly palatable food (HPF) for 2 h during the light phase
(starting 2 h after the light onset). The HPF (3.63 kcal/g) was a mix of
52% Nutella (Ferrero) chocolate cream (5.33 kcal/g; 56%, 31%, and 7%
from carbohydrate, fat, and protein, respectively), 33% grounded food
pellets (standard rat chow, Mucedola, 4RF18), and 15% water (w/w per-
cent ratio). On the first BE test day (25th day of the study), rats from the
restricted group were exposed to frustration stress. For 15min, the HPF
was placed inside a metallic grid container hanging on the anterior wall
of the cage, so that the rats were able to see and smell the HPF but were
not able to eat it (frustration stress). Subsequently, the HPF was placed
Table 1. Primer sequences used for scRT-PCR experimentsa
Pairs of primers (from 59 to 39)
Gene GenBank no. First-round PCR Second-round PCR
GAPDH AF106860.2 Sense CCTGCACCACCAACTGCTTAGC CCTGCACCACCAACTGCTTAGC
Antisense CTCGGCCGCCTGCTTCAC ATGTCAGATCCACAACGGATACATTGG
RXFP3 NM_001008310.1 Sense CAAGCTCCTGGGTTGGGACC CAAGCTCCTGGGTTGGGACC
Antisense GCATTAAGTGGCGCCAGGGC GGCGCACTAAGCAGTAGAGGAT
KCNQ2 NM_133322.1 Sense GTGCTGATTGCCTCCATTGCTG GTGCTGATTGCCTCCATTGCTG
Antisense CCAATGGTTGTCAGGGTGATCAG GGCCAGGATGAGGCAGAGG
KCNQ3 NM_031597.4 Sense CTATTCGGACCACATCTCACCC CTATTCGGACCACATCTCACCC
Antisense ACTACAGTACCAGGAGTCAGCC CATAGGCATGGATCCACTGGG
KCNQ4 XM_233477.8 Sense GACGATTACACTGACGACCATTGG GACGATTACACTGACGACCATTGG
Antisense CCAGGGCAGAAGGAGGCAC CTCAAACAAGAGGGCCAGCTC
KCNQ5 XM_001071249.3 Sense GCTGGGCTCCGTGGTTTACG GCTGGGCTCCGTGGTTTACG
Antisense CTTCTGCACTTTGGTGGGGCTG GCTTGCTGCCTCCCCTTGTTC
aGenBank accession number and sequences of primers used for each of the examined genes in both rounds of PCR.
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inside the cage and rats started to eat. Rats in the nonrestricted group
had immediate access to the HPF, without frustration stress; therefore,
the final profile of the experimental groups was restricted and stressed
(binge-eaters [BE]), and nonrestricted and nonstressed (control). During
the test, the HPF intake was measured over 2 h in several discrete time
points (starting ;2 h after the light onset). Three days after the first BE
test, a fourth 8-d-long cycle of food restriction and refeeding was started
in the BE group, and constant ad libitum access to chow was maintained
in the control group. Subsequently, the second BE test (37th day of the
study) was conducted (for the protocol timeline, see Fig. 5A). On BE test
days, bilateral intra-PVN injection were made immediately before the
frustration stress (BE group) or 15min before access to HPF (control
group). Before each test, half the rats was injected with R3(B1-22)R and
half with vehicle; these conditions were switched between the first and
second test, so each rat received both (R3(B1-22)R and vehicle) in sepa-
rate tests.
After the experiment, brains were collected, frozen in 40°C
isopentane, and stored at80°C until being cut on a cryostat into cor-
onal 40mm sections to verify the correct bilateral PVN targeting. The
sections were examined under a light microscope (Leica DMR, Leica
Microsystems) equipped with a camera (DS-Ri2, Nikon Instruments).
Based on cannulae placement, 2 rats were excluded from the final analy-
sis of HPF intake (1 control, 1 BE).
Experimental design and statistical analysis. Electrophysiological
data were analyzed using custom Spike2 and MATLAB (The
MathWorks) scripts as well as Mini Analysis software (Synaptosoft) in
the case of postsynaptic current recordings. The change in membrane
potential or whole-cell current in response to the peptide application
was considered significant if it differed from the baseline by .3 SDs.
The I–V relationship of RXFP3-A2-induced whole-cell current and its
blockade by XE991 was statistically analyzed in a group of MNCs re-
sponsive to RXFP3-A2 at a command potential of 50mV. For postsy-
naptic current analysis, two 200 s whole-cell recordings (one from the
baseline period before drug application, and another 300 s later) were
analyzed using Mini Analysis software. Events were manually detected
to measure frequency, mean rise time, mean amplitude, and decay time
constant of averaged current trace; these parameters were subjected to
statistical analysis (baseline vs peptide application). Analysis of postsy-
naptic currents was restricted to MNCs in which drug application
induced an outward whole-cell current. Repeated-measures two-way
ANOVA, paired t test, unpaired t test with Welch’s correction, and
Fisher’s exact test were used for statistical comparisons; and the applica-
tion of each specific test is indicated in Results.
In the scRT-PCR experiments, only neurons with detectable
GAPDH expression were included in the final analysis. A x 2 test was
used to compare the proportion of male and female neurons expressing
the detected mRNA species.
The distribution of RLN3-ir fibers in the PVN area was reconstructed
based on z-stack images (10 optical slices, with a 1.480mm step size,
1388 1040 pixels) combined into projections and stitched using
ImageJ (Schneider et al., 2012) and CorelDraw software, respectively.
Images corresponding to the selected plates of a rat brain atlas (distance
from bregma: from 1.92 to 1.56 mm) (Paxinos and Watson, 2007)
were further processed using a local thresholding method (Bernsen,
radius= 1 pixel, contrast threshold= 25) and an Analyze Particles option
(size = 0-300 pixel) to dissect the DAB-stained RLN3-ir fibers. Area frac-
tion was measured in defined bilateral ROIs, including the PVN area
and adjacent dorsal, lateral, and ventral regions, to determine the density
of stained fibers (see Figs. 5A, 4A). The distribution of fibers was com-
pared between ROIs and sexes using a repeated-measures two-way
ANOVA.
The HPF intake during the BE test was expressed as kcal/kg of body
weight and compared between groups (control vs BE) and treatments
(ACSF vs R3(B1-22)R), using a two-way ANOVA.
The test used is indicated in the Results. Data were considered to
be significantly different at p, 0.05. All tests were two-tailed. All val-
ues are presented as mean 6 SD. Statistical analysis was performed
using GraphPad Prism version 6.00 for Windows (GraphPad
Software).
Results
RLN3/RXFP3 signaling inhibits a majority of PVNMNCs in
male and female rats
In a series of whole-cell recordings ex vivo, we investigated the
effects of RLN3 and a selective, high-affinity RXFP3 agonist pep-
tide on the electrophysiology of PVN MNCs in male and female
Sprague Dawley rats, and explored possible sex differences in
recorded responses.
Initially, the responsiveness to RLN3 (100 nM, final bath con-
centration) was characterized. MNCs (9 MNCs from male and 8
MNCs from female rats) were voltage-clamped at 50mV and
recorded in the presence of the voltage-gated sodium channels
blocker, TTX, and the antagonists of ionotropic glutamate and
GABA receptors, CNQX, DL-AP5, and bicuculline, to eliminate
possible presynaptic and polysynaptic effects. In a vast majority
of MNCs (100% of MNCs from male rats and 88% of MNCs
from female rats), bath administration of RLN3 enhanced out-
ward whole-cell current recorded at the 50mV command
potential (Fig. 1A-C). Additionally, in the presence of RLN3, an
augmented outward current (or decreased inward current) was
recorded in response to a brief change (1.5 s) in command
potential to 30 and 20mV in a majority of RLN3-responsive
MNCs (Fig. 1D).
As RLN3 can also bind and activate the relaxin receptor,
RXFP1, which is present in the rat PVN, we tested the RXFP3-
dependent nature of RLN3 actions. In a subset of neurons (four
MNCs frommale and three MNCs from female rats), after appli-
cation of RLN3, the peptide was reapplied in the presence of the
potent RXFP3 antagonist, R3(B1-22)R (20 mM) (Haugaard-
Kedström et al., 2011). Under these conditions, RLN3 had no
effect or the amplitude of the RLN3-induced outward current
was substantially reduced; both at the command potential of
50mV (repeated-measures two-way ANOVA, antagonist treat-
ment: F(1,5) = 14,64, df = 1, p=0.0123) and during brief depolariz-
ing pulses to 30 (paired t test: t= 4.253, df = 5, p=0.0081) and
20mV (paired t test: t=3.912, df = 5, p= 0.0113; Fig. 1A,E,F).
No sex differences were observed in the proportion of neurons
responsive to RLN3 (Fisher’s exact test: p. 0.05) or the ampli-
tude of RLN3-induced current at any tested command potential
(unpaired t test with Welch’s correction: p. 0.05). Similarly,
there were no sex differences or interaction in blockage of
RLN3-induced current by the RXFP3 antagonist (repeated-meas-
ures two-way ANOVA, sex, and interaction of sex and antago-
nist treatment: p. 0.05). Since the influence of RLN3 on MNC
electrophysiology was RXFP3-dependent, subsequent experi-
ments were performed using the selective RXFP3 agonist,
RXFP3-A2 (600 nM) (Shabanpoor et al., 2012).
The influence of selective RXFP3 activation on spontaneous
PVN MNC activity was investigated in normal ACSF in a zero
current-clamp mode (10 MNCs from male and 12 MNCs from
female rats). The majority of MNCs were inhibited by RXFP3-
A2 (90% of male and 92% of female MNCs; Fig. 2A); bath appli-
cation of the peptide resulted in a reduction or cessation of firing
and/or membrane hyperpolarization (Fig. 2A,B). The RXFP3-
induced inhibition of neuronal activity was accompanied by a
decrease in membrane resistance in a majority of responsive neu-
rons, pointing to an increase in the ionic conductance underlying
the observed hyperpolarization (in 88% of male and 78% of
female MNCs; Fig. 2C). To verify the postsynaptic character of
RXFP3-induced inhibition, a subset of RXFP3-A2-responsive
MNCs (7 MNCs from male and 9 MNCs from female rats) was
reexposed to the drug in the presence of TTX, CNQX, DL-AP5,
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and bicuculline. All tested MNCs remained responsive to
RXFP3-A2 under these conditions (Fig. 2A,B). Again, no sex dif-
ferences were observed in the proportions of RXFP3-A2-respon-
sive MNCs (Fisher’s exact test: p. 0.05), agonist-evoked change
in spiking frequency, membrane potential, or input resistance
(unpaired t test withWelch’s correction: p. 0.05).
Next, the influence of selective RXFP3 activation on MNC
whole-cell current was tested. MNCs (74 from male and 77 from
female rats) were voltage-clamped at a command potential
of 50mV and recorded in ACSF containing TTX, CNQX,
DL-AP5, and bicuculline. Under these conditions, RXFP3-A2
induced an outward whole-cell current in a majority of tested
MNCs (in 88% of male and 90% of female MNCs; Fig. 2D-F).
Moreover, current responses to brief (1.5 s) changes of command
potential to 30 and 20mV were analyzed in a subset of neu-
rons (25 MNCs from male and 31 MNCs from female rats). In a
majority of RXFP3-A2-responsive MNCs, an increased outward
current (or decreased inward current) was observed in a whole-
cell current recorded at these potentials during the agonist action
(Fig. 2G). Additionally, we analyzed current responses to brief (1
s) hyperpolarizing steps to a command potential of 100mV in
a subset of neurons (28 MNCs from male and 33 MNCs from
female rats). In a majority of RXFP3-A2-sensitive MNCs (57%
males and 61% females), no change was observed in whole-cell
current recorded at 100mV during the agonist action (Fig.
2H). As in our recording conditions, the calculated reversal
potential for K1 equals 102mV (similar to the command
potential during hyperpolarizing steps), a lack of RXFP3-A2-
induced current at this potential, with a simultaneous robust
effect present at50mV, points to the possible involvement of a
K1 conductance in the action of RXFP3-A2. In contrast, in the
remaining, smaller subset of RXFP3-A2-sensitive MNCs (43% in
males and 39% in females), the outward current induced by
RXFP3 activation at50mV was accompanied by an increase in
the inward current recorded at 100mV, pointing to activation
of an additional excitatory conductance in some MNCs (Fig. 2H).
Again, no sex differences were observed either in the proportion
of neurons responsive to RXFP3-A2 (Fisher’s exact test: p. 0.05)
or the amplitude of RXFP3-A2-induced current at any command
potential (unpaired t test with Welch’s correction: p. 0.05).
Postrecording immunohistochemical identification of MNCs
revealed that both OXT-ir and AVP-ir MNCs were sensitive
to RXFP3-A2 (Fig. 2I,J). No differences were observed among
male and female OXT-ir and AVP-ir MNCs in the amplitude of
the RXFP3-A2-induced current (repeated-measures two-way
ANOVA, peptide content, sex, and interaction of peptide con-
tent and sex: p. 0.05; Fig. 2K). Therefore, data from all MNCs
were pooled.
RXFP3-mediated inhibition is caused by a potassium
conductance resembling an M-current
After observing the effect of the RXFP3-A2 peptide and its termi-
nation and washout, RXFP3-A2 was reapplied under several ex-
perimental conditions to investigate the ionic mechanism(s)
underlying the RXFP3-induced inhibition of PVN MNCs. As no
statistically significant sex differences or interactions of sex and
pharmacological treatment were observed in any of these experi-
ments (repeated-measures two-way ANOVA, sex and interaction
of sex and pharmacological treatment: p. 0.05), data obtained
frommale and female rats were pooled.
Reexposure to RXFP3-A2 under the same conditions as the
first application (ACSF containing TTX and blockers of synaptic
transmission) induced an outward current of a comparable
magnitude, consistent with a lack of RXFP3 desensitization or
internalization following initial or repeated stimulations (9
MNCs, repeated-measures two-way ANOVA, repeated agonist
treatment: p. 0.05; Fig. 3A,B).
Figure 1. RLN3 induces an RXFP3-dependent outward whole-cell current in a majority of PVN MNCs from male and female rats. A, RLN3-induced outward whole-cell current (voltage-clamp
recording, command potential 50mV) during pharmacological deafferentation (TTX, DL-AP5, CNQX, BIC) and its blockade by a potent RXFP3 antagonist, R3(B1-22)R. Marked areas represent
voltage-clamp stimulations to30 and20mV (example shown in D). Black represents baseline. Red represents response to RLN3. B, Amplitude of RLN3-induced outward whole-cell current
in MNCs from male and female rats at the command potential of 50mV. No significant sex difference was observed (unpaired t test with Welch’s correction, p. 0.05). C, Proportion of
RLN3-responsive versus nonresponsive MNCs in voltage-clamp recordings. No significant sex difference was observed (Fisher’s exact test, p. 0.05). D, RLN3-induced whole-cell outward current
during voltage stimulation to 30 and 20mV. Inset, Stimulation protocol. Note the absence of the RLN3-induced effect in the presence of R3(B1-22)R (F). Graph represents the amplitude
of RLN3-induced current and the proportion of RLN3-responsive male and female MNCs displaying a RLN3-induced change in current at given membrane potentials. Color represents effect.
White represents no effect. No significant sex difference was observed in current amplitude (unpaired t test with Welch’s correction, p. 0.05) or in the proportions of MNCs with an RLN3-
induced change during voltage stimulations (Fisher’s exact test, p. 0.05). E, RLN3-induced current amplitude at command potential of50mV under control conditions and in the presence
of R3(B1-22)R. *p, 0.05, significant influence of treatment with R3(B1-22)R (repeated-measures two-way ANOVA). No significant sex difference or interaction of sex and treatment were
observed (p. 0.05). F, Blockade of RLN3-induced current during stimulation to 30 and 20 mV in the presence of R3(B1-22)R. Inset, stimulation protocol. Note the absence of RLN3-
induced effect. Graph represents the blockade of RLN3-induced current during stimulation expressed as the remaining percentage of the RLN3-induced current amplitude under paired control
conditions. *p, 0.05 and **p, 0.01 indicate the significant reduction tested using an unpaired t-test with Welch’s correction. All error bars represents SD.
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To verify the hypothesis that RXFP3
activation leads to increased potassium
conductance, a modified ACSF con-
taining an elevated K1 concentration
(final concentration: 21.6 mM, with a
simultaneously reduced NaCl concen-
tration) was used in this subset of
experiments. Under these conditions,
EK equaled the command potential
(50mV), and the RXFP3-A2 effect
was almost completely abolished (12
MNCs, 94% reduction in RXFP3-A2-
induced current amplitude compared
with the first peptide application,
repeated-measures two-way ANOVA,
high K1 treatment: F(1,10) = 32.89, df = 1,
p=0.0002; Fig. 3A,C).
The RXFP3-A2-induced current was
also reduced in the presence of cadmium
ions (Cd21), a blocker of Ca21 conduc-
tances (Hille, 2001), confirming our pre-
vious observation in Wistar male rats
(Kania et al., 2017). Addition of CdCl2
(200 mM) to the bathing solution reduced
the amplitude of RXFP3-A2-induced
current by 60% compared with the
effect produced by the first application
(13 MNCs, repeated-measures two-way
ANOVA, Cd21 treatment: F(1,11) =
11.39, df = 1, p=0.0062; Fig. 3A,D).
Therefore, these data suggest that the
RXFP3-A2-induced potassium current
might be Ca21-dependent.
Next, as the presence of a Ca21-de-
pendent M-like conductance was reported
in MNCs (W. Zhang et al., 2009), we
tested whether the RXFP3-A2-induced
current could be blocked by the M-
current inhibitor XE991 (Jentsch,
2000). Indeed, XE991 dose-depend-
ently blocked the current activated by
the RXFP3 activation: 10 mM XE991
reduced its amplitude by 34% (21
MNCs, repeated-measures two-way
ANOVA, 10 mM XE991 treatment:
F(1,18) = 17.30, df = 1, p = 0.0006),
Figure 2. RXFP3 activation with a selective agonist, RXFP3-A2, is inhibitory in the majority of PVN MNCs from male and female
rats. A, RXFP3-A2-induced inhibition of spiking and hyperpolarization (current-clamp recording, zero-current mode).
Hyperpolarization persists during blockade of spiking and pharmacological deafferentation (in ACSF with TTX, DL-AP5, CNQX, BIC).
Inset, The proportion of RXFP3-A2-responsive versus nonresponsive MNCs in current-clamp recordings. No significant sex differ-
ence was observed (Fisher’s exact test, p. 0.05). B, RXFP3-A2-induced reduction of spiking frequency (recorded in normal
ACSF), and RXFP3-A2-induced membrane hyperpolarization (recorded in ACSF with TTX, DL-AP5, CNQX, BIC). No significant sex
difference in either parameter was observed (unpaired t test with Welch’s correction, p. 0.05). C, RXFP3-A2-induced reduction
of voltage responses to hyperpolarizing current pulses indicating a decrease in input resistance. Inset, Stimulation protocol. Traces
come from the recording in A (marked with asterisks). Graph represents the calculated change in input membrane resistance and
the proportion of male and female RXFP3-A2-inhibited MCNs displaying an accompanying decrease in input membrane resist-
ance. Color represents effect. White represents no effect. No significant sex difference was observed in the RXFP3-A2-induced
change (unpaired t test with Welch’s correction, p. 0.05) or the proportions of MNCs with an RXFP3-A2-induced decrease in
input resistance accompanying the RXFP3-A2-induced inhibition (Fisher’s exact test, p. 0.05). D, RXFP3-A2-induced outward
whole-cell current (voltage-clamp recording, command potential 50mV) during pharmacological deafferentation (TTX, DL-AP5,
CNQX, BIC). Marked areas represent voltage-clamp stimulations to 30 and 20mV (example shown in G). Black represents
baseline. Red represents response to RXFP3-A2. E, Amplitude of RXFP3-A2-induced outward whole-cell current in MNCs from male
and female rats at command potential of50mV. No significant sex difference was observed (unpaired t test with Welch’s correc-
tion, p. 0.05). F, Proportion of RXFP3-A2-responsive versus nonresponsive MNCs in voltage-clamp recordings. No significant sex
difference was observed (Fisher’s exact test, p. 0.05). G, RXFP3-A2-induced whole-cell outward current during voltage stimulation
to 30 and 20mV. Inset, Stimulation protocol. Graph represents the amplitude of RXFP3-A2-induced current and proportion of
RXFP3-A2-responsive male and female MNCs displaying RXFP3-A2-induced change in whole-cell current at given membrane poten-
tials. Color represents effect. White represents no effect. No significant sex difference was observed in current amplitude (unpaired
t test with Welch’s correction, p. 0.05), or in the proportions of MNCs with an RXFP3-A2-induced change during voltage stimula-
tions (Fisher’s exact test, p. 0.05). H, RXFP3-A2-induced whole-cell inward current during voltage stimulation to 100 mV in a
minor subset of MNCs. Inset, stimulation protocol. Graph represents the amplitude of the RXFP3-A2-induced current and proportion
of male and female RXFP3-A2-responsive MCNs displaying increased inward whole-cell current at the command potential of
/
100 mV. Color represents effect. White represents no
effect. No significant sex differences were observed in the
amplitude of RXFP3-A2-induced current (unpaired t test
with Welch’s correction, p. 0.05), or in the proportions
of MNCs with RXFP3-A2-induced change during voltage
stimulations (Fisher’s exact test, p. 0.05). I, J, Series of
fluorescent projection images of biocytin-filled OXT-ir (in I)
or AVP-ir (in J) MNCs (white arrowhead). Scale bar,
10mm. K, Amplitude of RXFP3-A2-induced outward
whole-cell current (command potential 50mV) in OXT
and AVP MNCs from male and female rats. No significant
effects of peptide content, sex, and interaction of peptide
content and sex were observed in the amplitude of RXFP3-
A2-induced outward whole-cell current (two-way ANOVA,
p. 0.05). All error bars represents SD.
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whereas 50 mM XE991 reduced it
by 104% compared with the first pep-
tide application (8 MNCs, repeated-
measures two-way ANOVA, 50 mM
XE991 treatment: F(1,6) =24.05, df=1,
p = 0.0027; XE991: 10 mM vs 50 mM,
two-way ANOVA, XE991 concentra-
tion: F(1,23) =20.73, df=1, p = 0.0001;
Fig. 3A,E,F). In one MNC, the block-
ade of the RXFP3-A2-induced out-
ward current with XE991 (10 mM)
revealed a strong RXFP3-A2-induced
inward current. This cell was excluded
from the analysis.
In a group of MNCs recorded at a
command potential of 50mV, with
brief voltage stimulations to 100mV
(1 s), as well as 30 and 20mV (1.5
s) throughout recording, an I–V rela-
tionship of RXFP3-A2-induced cur-
rent and its blockade by XE991 was
analyzed (14 MNCs treated with 10
mM XE991 and 6 MNCs treated with
50 mM XE991). Both concentrations
of XE991 dose-dependently blocked
the RXFP3-A2 induced current in a
potential-dependent manner (RXFP3-
A2 effect blockade with 10 mM XE991,
14 MNCs, repeated-measures two-way
ANOVA, 10 mM XE991 treatment for:
100mV, p. 0.05; 50mV, F(1,12) =
10.68, df=1, p = 0.0067; 30mV,
F(1,12) = 6.259, df = 1, p = 0.0278;
20mV, F(1,12) = 6.259, df = 1,
p = 0.0278; RXFP3-A2 effect block-
ade with 50 mM XE991, 6 MNCs,
repeated-measures two-way ANOVA,
50mM XE991 treatment for:100mV,
p. 0.05; 50mV, F(1,4)=76.29, df=1,
p=0.0009; 30 mV, F(1,4)=37.18,
df=1, p=0.0037; 20mV, F(1,4) =
16.71, df=1, p = 0.0150; Fig. 3E-G).
The neural M-current is mainly
mediated by ionic channels composed
by four members of the KCNQ trans-
membrane subunit family (KCNQ2-
5), with different homodimer and
heterodimer combinations forming
channels of varying electrical and
pharmacological properties (for review,
see Jentsch, 2000; Robbins, 2001;
Brown and Passmore, 2009). Exp-
ression of KCNQ subunits has been
observed in PVN (Zhou et al., 2017)
and MNCs of SON (W. Zhang et al.,
2009); therefore, using sc-RT-PCR,
we examined possible coexpression
of RXFP3 and KCNQ channel subu-
nits in the PVN MNCs to determine
possible molecular substrates for the
modulation of the M-current by the
RLN3/RXFP3 signaling. After whole-
cell recordings, the cytoplasm of single
Figure 3. RXFP3 activation induces M-like potassium current. A, RXFP3-A2-induced outward current at a command potential of50mV
under several different conditions expressed as a remaining percentage of the RXFP3-A2-induced current amplitude under paired control con-
ditions. Triangle represents male. Circle represents female. **p, 0.01; ***p, 0.001; ****p, 0.0001; significant influence of treatment
with the compound (repeated-measures two-way ANOVA). No significant sex differences or interaction of sex and treatment were observed
(p. 0.05). Note the significant dose-dependent effect of XE991. ***p,0.001, significant influence of the XE991 concentrations (two-way
ANOVA). No significant sex differences or interaction of sex and XE991 concentration were observed (p. 0.05). B-E, RXFP3-A2-induced out-
ward whole-cell current (command potential 50mV) during pharmacological deafferentation (TTX, DL-AP5, CNQX, BIC) and reexposure to
RXFP3-A2 under several conditions: control (repeated RXFP3 application with no additional compound, in B) increased extracellular [K1] in
the ACSF (in C), presence of Cd21 (200mM, in D), and presence of XE991 (50 mM, in E). E, Marked areas represent voltage-clamp stimula-
tions to 30 and 20mV (example shown in F). Black represents baseline. Red represents response to RXFP3-A2. F, RXFP3-A2-induced
whole-cell outward current during voltage stimulation to30 and20mV. Inset, Stimulation protocol. Note the absence of the RXFP3-A2-
induced effect in the presence of XE991 (50mM). G, The I–V relationship of RXFP3-A2-induced outward whole-cell current under control con-
ditions and in the presence of XE991 (10 and 50 mM, respectively). Note the dose-dependent blockade of RXFP3-A2-induced current by
XE991. *p, 0.05; **p, 0.01; ***p, 0.001; significant influence of treatment with XE991 (repeated-measures two-way ANOVA). No sig-
nificant sex differences or interaction of sex and treatment were observed (p. 0.05). H, Proportions of male and female MNCs expressing
and coexpressing RXFP3 and KCNQ subunit mRNA detected by sc-RT-PCR. Only MNCs with detectable GAPDH mRNA were analyzed. KCNQ4
and KCNQ5 mRNA was not detected in our PVN MNCs preparations. No significant sex difference in these proportions was observed (x 2 test,
p. 0.05). Image represents exemplary sc-RT-PCR data from three female MNCs. All error bars represents SD.
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MNCs was aspirated into the 1-2 MX resistance patch micropip-
ettes and used for sc-RT-PCR. A combination of specific pri-
mers was used to detect several mRNA species: RXFP3,
KCNQ2-5, and GAPDH (only samples verified to express
GAPDH mRNA were analyzed). A total number of 40 MNCs
(21 from males and 19 from females) were included in this
analysis. We observed the frequent presence of RXFP3
mRNA (in 67% male and 53% female MNCs) and KCNQ2
mRNA (in 76% male and 74% female MNCs), and individual
MNCs expressing KCNQ3 mRNA (1 neuron from male and
2 neurons from female MNCs), whereas KCNQ4 and
KCNQ5 mRNA were not detected (Fig. 3H). Notably, the
majority of KCNQ2 mRNA-expressing MNCs coexpressed
RXFP3 mRNA (69% male and 64% female MNCs). No sex
difference in the proportions of MNCs expressing specific
mRNA species was observed (x 2 test, p. 0.05).
Synaptic input to PVNMNCs is unaffected by RXFP3
activation
In a separate series of whole-cell experiments, we investigated
the possible effect of RLN3 (100 nM) and RXFP3-A2 (600 nM) on
spontaneous and miniature synaptic currents in MNCs (both
excitatory and inhibitory). Neurons were voltage-clamped at
50mV, and synaptic currents were recorded in normal or
TTX-containing ACSF. Separate subsets of neurons were tested
with either RLN3 (20 MNCs from male and 19 MNCs from
female rats) or RXFP3-A2 (20 MNCs from male and 17
MNCs from female rats). Neither peptide significantly influ-
enced any of the following parameters of spontaneous/mini-
ature synaptic activity: frequency, amplitude, rise time, or
decay time constant of both IPSCs and EPSCs (repeated-
measures two-way ANOVA, RLN3 or RXFP3-A2 treatment,
sex, and interaction of RLN3 or RXFP2-A2 treatment and
sex: p. 0.05; Table 2).
RLN3 neurons innervate the vicinity of the PVN
Our previous studies in male Wistar rats revealed that dense
RLN3-ir fibers surround the PVN, and only rare fibers enter the
main soma-rich nucleus area (Kania et al., 2017). Here, to further
characterize the anatomy of the RLN3 input to the PVN in male
and female Sprague Dawley rats, we performed immunohisto-
chemical and neural tract-tracing studies. Coronal hypothalamic
sections throughout the PVN from males and females were im-
munostained to visualize RLN3-ir fibers. We observed an abun-
dance of RLN3-ir fibers at the PVN border proximity and scarce
RLN3 innervation of the nucleus itself. Quantitative analysis of
Table 2. Synaptic input to PVN MNCs is unaffected by RLN3 and a selective RXFP3 agonista
Inhibitory Excitatory
Male (N= 11) Female (N= 9) Male (N= 11) Female (N= 9)
Baseline RLN3 Baseline RLN3 Baseline RLN3 Baseline RLN3
RLN3
Spontaneous synaptic activity
Frequency (Hz) 8.96 5.4 9.26 5.7 7.86 5.9 7.96 5.7 1.36 1.0 1.26 0.6 0.86 0.3 0.96 0.4
Mean amplitude (pA) 33.66 9.6 32.76 9.9 31.06 5.4 30.26 4.6 18.96 2.7 18.96 3.4 21.66 3.5 21.36 3.5
Mean rise time (ms) 2.86 0.4 2.86 0.3 2.76 0.3 2.76 0.2 2.46 0.2 2.36 0.1 2.46 0.2 2.46 0.2
Decay time constant (ms) 5.56 1.3 5.66 1.3 5.06 1.2 4.96 1.0 2.36 0.8 2.36 0.6 2.16 0.5 2.06 0.5
Male (N= 9) Female (N= 10) Male (N= 9) Female (N= 10)
Baseline RLN3 Baseline RLN3 Baseline RLN3 Baseline RLN3
Miniature synaptic activity
Frequency (Hz) 10.16 6.0 9.56 5.3 6.46 4.4 6.46 4.5 1.56 1.6 1.16 0.6 0.96 0.4 0.96 0.4
Mean amplitude (pA) 25.86 3.8 26.16 4.0 26.16 5.6 25.76 5.3 19.66 5.3 18.96 3.6 16.36 3.4 16.36 3.2
Mean rise time (ms) 2.66 0.2 2.66 0.2 2.66 0.2 2.66 0.2 2.36 0.1 2.36 0.1 2.36 0.2 2.46 0.1
Decay time constant (ms) 4.76 0.8 4.71 0.7 4.96 0.9 5.16 0.8 2.16 0.9 1.86 0.7 2.06 0.6 2.06 0.5
Male (N= 10) Female (N= 9) Male (N= 10) Female (N= 9)
Baseline A2 Baseline A2 Baseline A2 Baseline A2
RXFP3-A2
Spontaneous synaptic activity
Frequency (Hz) 8.66 7.3 8.46 7.1 11.36 6.7 11.06 6.5 1.06 0.8 1.06 0.6 1.16 0.6 1.16 0.5
Mean amplitude (pA) 32.06 5.5 31.86 6.3 34.16 7.4 33.06 7.2 19.56 4.8 20.96 6.3 19.76 2.3 20.06 3.0
Mean rise time (ms) 2.86 0.3 2.76 0.2 2.86 0.2 2.86 0.2 2.46 0.2 2.46 0.2 2.36 0.1 2.36 0.1
Decay time constant (ms) 5.96 1.1 5.76 1.1 5.86 1.3 5.96 1.2 3.06 1.6 2.76 1.2 2.16 0.5 2.16 0.4
Male (N= 10) Female (N= 8) Male (N= 10) Female (N= 8)
Baseline A2 Baseline A2 Baseline A2 Baseline A2
Miniature synaptic activity
Frequency (Hz) 6.86 3.2 6.76 3.0 7.86 3.7 7.36 3.7 1.06 0.5 1.16 0.5 0.76 0.4 0.76 0.4
Mean amplitude (pA) 28.76 5.7 29.26 5.6 32.56 3.2 32.86 3.5 19.66 4.1 19.86 3.2 19.46 1.1 19.36 2.5
Mean rise time (ms) 3.16 0.4 3.06 0.3 3.16 0.8 3.06 0.3 2.86 0.3 2.96 0.2 2.86 0.2 2.86 0.2
Decay time constant (ms) 4.76 1.1 4.76 0.9 4.06 0.5 4.26 0.4 2.26 1.1 2.16 1.0 2.06 0.7 1.96 0.4
aSpontaneous and miniature postsynaptic currents recorded from male and female MNCs under two experimental conditions: baseline and after application of RLN3 or RXFP3-A2. No significant effect of treatment, sex, or inter-
action of treatment and sex were observed in all of the cases analyzed (repeated-measures two-way ANOVA, p. 0.05).
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fiber densities within the PVN and the peri-PVN zone revealed stat-
istically significant differences (Fig. 4A-C). Moreover, ANOVA
revealed sex differences and interaction of sex and analyzed area
(PVN vs peri-PVN zone) with females displaying a higher fiber
density than males and the difference being more profound in the
perinuclear zone (repeated-measures two-way ANOVA, PVN vs
peri-PVN zone: F(1,10) =20.55, df=1, p=0.0011; sex: F(1,10) =8.190,
df=1, p=0.0169; interaction of PVN vs peri-PVN zone and sex:
F(1,10) =5.429, df=1, p=0.0421).
In a series of double neural tract-tracing experiments,
FluoroGreen and FluoroRed retrograde tracers were injected
bilaterally into the PVN area of male and female Sprague Dawley
rats. Coronal sections from all rat brain areas where RLN3-syn-
thesizing neurons are located (PAG, PnR, dSN, and NI) were im-
munostained for RLN3 and examined for colocalization of tracer
and peptide. Sparse retrogradely filled RLN3-ir neurons were
observed in the NI, whereas only individual retrogradely labeled
RLN3-ir neurons were present in the PAG, PnR, and dSN (Table
3; Fig. 4D). In line with the low RLN3 fiber density in the PVN
and high density in the perinuclear zone, the number of tracer-
positive RLN3-ir neurons depended on the size and precise local-
ization of the tracer injection site. Injections restricted to the
PVN area revealed a more scarce RLN3 innervation (mainly NI
originating), than tracer injections extending beyond the PVN
soma boundary, which resulted in considerably higher number
of retrogradely filled, RLN3-positive neurons (Table 3; Fig. 4E,
F). Additionally, the mean number of tracer-positive RLN3-ir
neurons was highest when the injections beyond the PVN border
were localized in the mid-region of the PVN anterior-posterior
axis, and lower after perinuclear zone injections restricted to the
posterior part of the nucleus (Table 3). Notably, the number of
retrogradely labeled neurons was substantially higher ipsilateral
to the injection site. This lateralization was most profound in the
NI (Table 3; Fig. 4E,F).
No qualitative sex differences were observed in the source of
the RLN3 innervation of the PVN and its vicinity, with PVN-
innervating RLN3 neurons present in all examined areas in male
and female rats.
RXFP3 activation in the PVN is necessary for the occurrence
of BE behavior
RLN3/RXFP3 signaling has been linked to binge-like eating
(Lenglos et al., 2013; Calvez et al., 2016b); so to further assess the
involvement of PVN RXFP3 in this phenomenon, we used an
established rat model of BE (Cifani et al., 2009; Piccoli et al.,
2012; Micioni Di Bonaventura et al., 2017) combined with intra-
Figure 4. NI RLN3 neurons innervate the PVN and its adjacent areas, with a higher fiber
density in female than in male rats. A, Schematic representation of areas analyzed for DAB-
stained RLN3 fibers in the PVN and adjacent perinuclear zone (PZ). Scale bar, 200mm. B,
Area fraction of RLN3-ir fibers in the analyzed areas. Between-subjects statistical testing with
repeated-measures two-way ANOVA revealed the significant effect of the area of interest
(PVN vs PZ, *p, 0.05), sex (males vs females, ††p ,0.01), as well as interaction
(‡p, 0.05), pointing to a higher density of RLN3-ir fibers in the peri-PVN zone than in the
PVN and in females than in males, with a more profound sex difference observed in the
peri-PVN zone. C, Light microscopic projection images of DAB-stained RLN3-ir fibers in
the PVN and PZ area of male (left) and female (right) rats. Images are magnifications of the
areas marked with black squares in A. Note the difference between the PVN and the peri-
PVN zone. Scale bar, 20mm. D, Confocal projection image illustrating RLN3-ir neurons (cyan)
/
and neurons filled with retrograde tracer (FluoroRed, magenta) in the NI. Magnification of
the area indicated by a white rectangle represents RLN3-ir neurons, RLN3-ir/FluoroRed-posi-
tive neurons (white arrowheads), and RLN3-negative/FluoroRed-positive neuron (empty
arrowhead). Distance from bregma indicated. Scale bars: top, 200mm; bottom, 20mm. E, F,
Exemplary injection sites of fluorescent retrograde tracers (FluoroGreen in E and FluoroRed in
F) and reconstructions of single NI sections showing the distribution of RLN3-ir neurons
(cyan circles), RLN3-ir/retrograde tracer-positive (green circles in E and red circles in F), and
RLN3-negative/retrograde tracer-positive (open green circles in E and open red circles in F).
The injection in E is restricted to the PVN, whereas the injection in F extends beyond the
PVN borders, resulting in different number of RLN3-ir/retrograde tracer-positive between
these two injections. Distance from bregma indicated. Scale bars: PVN reconstructions,
400mm; NI reconstructions, 200mm. 4V, Fourth ventricle; D, dorsal perinuclear zone of the
PVN; L, lateral perinuclear zone of the PVN; NIc, NI pars compacta; NId, NI pars dissipata;
PDTg, posterodorsal tegmental nucleus; PZ, perinuclear zone of the PVN; V, ventral perinu-
clear zone of the PVN. All error bars represents SD.
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PVN injections of the RXFP3 antagonist, R3(B1-22)R. This
model utilizes yo-yo dieting and exposure to frustration stress in
female Sprague Dawley rats (body weight of rats subjected to
cycles of food restriction fluctuates but does not differ on test
days, repeated-measures two-way ANOVA, restricted vs nonres-
tricted group: p. 0.05; time: F(24,432) = 34.81, df = 28, p, 0.0001;
interaction of restricted vs nonrestricted group and time:
F(24,432) = 13.03, df = 28, p, 0.0001; Fig. 5A,B) to produce
binging on HPF (Fig. 5C). We observed that bilateral intra-
PVN injections of R3(B1-22)R (0.1 mg in 0.5 ml of ACSF into
each side of the PVN) potently reduced the amount of HPF
consumed during a 2 h access period in BE rats, with no effect
on consumption by control rats (not exposed to cycles of
food restriction and frustration stress; 30min from access
to the HPF: two-way ANOVA, antagonist treatment:
F(1,30) = 14.91, df = 1, p = 0.0006; BE vs control group:
F(1,30) = 23.45, df = 1, p, 0.0001, interaction of antagonist
treatment and BE vs control group: F(1,30) = 9.919, df = 1,
p = 0.0037; 120min from access to the HPF: two-way
ANOVA, antagonist treatment: F(1,30) = 8.187, df = 1, p =
0.0076; BE vs control group: F(1,30) = 7.010, df = 1, p, 0.0128,
interaction of antagonist treatment and BE vs control group:
F(1,30) = 8.178, df = 1, p = 0.0076). Injection sites were histo-
logically verified after completion of the experiment (Fig.
5D). Only data from rats with correctly targeted injections
were analyzed.
Discussion
In these studies, we discovered that the inhibitory effect of
RXFP3 activation on the activity of PVN MNCs in rats of both
sexes is mediated by an M-like K1 current. Moreover, we
showed that RLN3 fibers are far less abundant in the PVN soma-
rich area than in the adjacent perinuclear zone region, suggesting
RLN3 actions via non-somatic sites and/or via volume transmis-
sion. Notably, higher intra- and peri-PVN RLN3-ir fiber den-
sities were observed in females, a possible anatomic substrate for
sex differences in susceptibility to BED. Finally, we demonstrated
that RXFP3 blockade in the PVN abolishes BE of HPF in female
rats.
Electrophysiological data and pharmacological evidence from
the current study indicate that the RXFP3-induced inhibition
of the PVN MNCs is mediated by activation of an M-like cur-
rent. The M-current is a voltage-dependent, slowly activating
and noninactivating K1 conductance, contributing to the resting
membrane potential and to action potential threshold; and is
Table 3. RLN3 neurons innervate PVN and its vicinitya
Retrogradely traced RLN3-ir neurons
PAG dSN PnR NI
Tracer injection site Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral Contralateral Ipsilateral
PVN Males (N= 3) 36 3 36 3 26 3 0 0 0 66 8 146 15
Females (N= 1) 3 9 3 0 0 0 6 12
PERI-PVN Males (N= 3) 36 3 76 5 26 2 56 5 26 2 16 2 406 44 986 76
Females (N= 7) 66 4 96 8 16 2 46 3 26 2 56 4 306 16 766 46
PERI-PVN posterior Females (N= 3) 16 2 46 3 16 2 16 2 16 2 26 3 96 9 256 18
aThe numbers of rln3-ir/retrograde tracer-positive neurons in all known brain areas that synthesize RLN3 in male and female rats, with regard to the injection site. Note the substantially higher number of RLN3-ir/retrograde
tracer-positive neurons ipsilaterally to the injection sites, as well as in cases where tracer injections extended beyond the PVN.
Figure 5. Injection of an RXFP3 antagonist into the PVN reduced BE in female rats. A, Timeline of the BE induction protocol. Rats in the BE group were subjected to three cycles of food
restriction (66% of regular chow intake) and refeeding (ad libitum chow), whereas the control group had ad libitum access to chow. Black arrowheads indicate access to the HPF for 2 h in both
groups. Double arrows indicate bilateral intra-PVN injections of vehicle (0.5ml) or R3(B1-22)R (0.1mg/0.5ml) made on the test day. In the BE group, injections were followed by frustration
stress procedure for 15 min, and both groups had 2 h access to the HPF afterward. After an additional cycle of restriction and refeeding, the test was repeated with reversed injection conditions,
so that at the end of the study, each rat received both vehicle and R3(B1-22)R in separate tests. B, Body weights of rats subjected (BE) or not (control) to cycles of intermittent food restriction
followed by refeeding. Between-subjects statistical testing with a repeated-measures two-way ANOVA revealed the significant effect of time (****p, 0.0001) and interaction of time and
group (‡‡‡‡p, 0.0001), with no differences observed between groups, pointing to time-dependent changes with no permanent differences in body weight between feeding conditions. C,
HPF intake at 30 and 120 min during the BE tests and the effect of intra-PVN injection of the RXFP3 antagonist, R3(B1-22)R. Between-subjects statistical testing with a two-way ANOVA
revealed a significant effect of the treatment (vehicle vs R3(B1-22)R, **p ,0.01, ***p, 0.001), experimental group (control vs BE, †p, 0.05, ††††p, 0.0001), and interaction
(‡‡p, 0.01), pointing to a higher HPF intake in BE than control rats and the effectiveness of RXFP3 antagonism to reduce the HPF intake only in the BE group. D, Reconstruction of the PVN
area on coronal brain sections representing the intra-PVN injections sites in rats included in the experiment. Distance from bregma indicated. Scale bar, 400mm. All error bars represents SD.
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involved in the regulation of membrane excitability (for review,
see Brown, 1988; Brown and Passmore, 2009; Greene and Hoshi,
2017). In agreement with our previous study in male Wistar rats
(Kania et al., 2017), we confirmed that, in Sprague Dawley rats,
the RXFP3-induced outward current is attenuated by external
Cd21, a potent blocker of Ca21 channels and Ca21-dependent
conductance (Hille, 2001).
The influence of Ca21 on the M-current is complex and
depends on the Ca21 concentration and the signaling cascade
involved, with calmodulin-KCNQ interactions and Ca21-de-
pendent suppression of M-currents being extensively studied
(Marrion, 1997; Delmas and Brown, 2005). In contrast, prevent-
ing Ca21 influx with dihydropyridine-type, L-type Ca21 channel
blockers suppressed the M-current in hippocampal neurons,
whereby 10 mM nimodipine reduced the M-current amplitude by
60% (Wu et al., 2008). Notably, 10 mM nifedipine reduced the
amplitude of M-currents in SON MNCs (W. Zhang et al., 2009),
and these authors reported that Cd21 significantly reduced the
amplitude of an osmosensitive M-like current in MNCs. In the
present study, we observed an increase in inward whole-cell cur-
rent recorded at the hyperpolarized membrane potential
(100mV) after RXFP3 activation in a subpopulation of PVN
MNCs. This may represent an enhanced Ca21 influx, which can
potentiate M-like currents, but the precise nature of this phe-
nomenon remains to be identified.
Our electrophysiological experiments focused on whole-cell
net current, so overlapping ionic conductances may have masked
the individual current kinetics. Yet, the current recorded during
voltage stimulations of PVN MNCs in the presence of RXFP3
agonist frequently resembled the delayed rectifier kinetics char-
acteristic of M-currents, and its involvement was further sup-
ported by the dose-dependent pharmacological blockade of
RXFP3-induced current by XE991. It should be noted that
XE991 does not selectively block M-current/KCNQ channels
and may influence other potassium channels (KCNA2 IC50
.100 mM, and KCND3 IC50 of 43 mM) (Wang et al., 1998).
Nonetheless, the concentrations used in the present study were
too low to strongly influence KCNA2 or KCND3, which contrib-
utes to transient A-currents that would have been largely inactive
in our recording protocol, as A-currents become only transiently
active on depolarization from a hyperpolarized membrane
potential. XE991 has been also shown to block ether-a-go-go-
related (ERG, KCNH family) K1 channels (Wang et al., 1998;
Elmedyb et al., 2007), which are present in PVN (Papa et al.,
2003) and also mediate M-like currents (Meves et al., 1999;
Selyanko et al., 1999; Hirdes et al., 2004). At the same time,
XE991 is not a potent ERG blocker (IC50 .100 mM); therefore,
the efficacy of the concentrations used in the present study (10
and 50 mM) suggests that its effects were mainly due to KCNQ
channels’ blockade.
In a majority of neurons expressing M-current, the underly-
ing ionic channels are composed of KCNQ2 and KCNQ3 subu-
nits heteromers, and KCNQ2 homomers (Brown and Passmore,
2009). In line with previous reports of KCNQ subunit expression
in SON MNCs (W. Zhang et al., 2009), here we observed coex-
pression of RXFP3 and KNCQ channel subunits in PVN MNCs,
with the KCNQ family represented mainly by KCNQ2, which
provides a possible molecular substrate for the modulation of the
M-current by RLN3/RXFP3 signaling.
Although RXFP3 has been shown to modulate synaptic
inputs to parvocellular PVN CRF neurons (C. Zhang et al., 2017)
and neurons of the bed nucleus of stria terminalis in mice (Ch’ng
et al., 2019), neither RLN3 nor a selective RXFP3 agonist
influenced excitatory NMDA/AMPA or inhibitory GABAA re-
ceptor-mediated postsynaptic currents (spontaneous and minia-
ture) recorded from PVN MNCs in our rat brain preparations.
We therefore conclude that RLN3 inputs primarily act on postsy-
naptically located RXFP3 to modulate MNC activity in the rat.
We observed no significant sex differences in the influence of
RLN3/RXFP3 signaling on MNC electrophysiology. Consequently,
the stronger orexigenic effect of central administration of RLN3 in
female than in male rats (Calvez et al., 2015, 2016a; Lenglos et al.,
2015) might be associated with the overall action of centrally
injected peptide at multiple sites, rather than a specific influence on
the PVN MNCs. Indeed, central RLN3 administration, leading to
increased food intake, has been accompanied by changes (some of
them sex-specific) in the expression of several hypothalamic peptide
mRNA species as well as increased c-fos mRNA in different hypo-
thalamic areas (Calvez et al., 2015, 2016a; Lenglos et al., 2015),
reflecting the broad influence of central peptide injection.
Our immunohistochemical and neural tract-tracing studies
characterizing the RLN3 innervation of the rat PVN are in line
with previous reports of scarce RLN3 fibers within the PVN and
a low number of PVN-innervating NI neurons (Olucha-
Bordonau et al., 2003; Ma et al., 2007). Similarly, the relative
abundance of RLN3 fibers in the peri-PVN zone and the higher
number of retrogradely labeled RLN3 neurons in cases involving
tracer outside the PVN borders were described in our earlier
study in male Wistar rats (Kania et al., 2017). The consistent
expression of RXFP3 in the majority of PVN MNCs and their
sensitivity to RXFP3 ligands suggest that this innervation pattern
may constitute the basis of volume transmission by the peptide
that is sufficient to modulate the MNC activity, in addition to ca-
nonical synaptic transmission. Sex differences in the RLN3
innervation of PVN, with females displaying a higher density of
RLN3-ir fibers, are in line with reports of higher levels of RLN3
mRNA in the female NI (Lenglos et al., 2013). These differences
point to higher levels of RLN3 release in female PVN and may
contribute to the increased susceptibility of females to BED, in
which the RLN3/RXFP3 signaling have been implicated (this
study; Lenglos et al., 2013; Calvez et al., 2016b).
Our neuropharmacological studies demonstrated that RXFP3
signaling in the PVN is involved in the BE of HPF in female rats.
In line with this observation, intracerebroventricular injection of
the RXFP3 antagonist, R3(B1-22)R, reduced HPF intake in rats
and mice (Smith et al., 2014; Calvez et al., 2016b). Moreover, ear-
lier reports using different experimental models of BE (Lenglos et
al., 2013; Calvez et al., 2016b) have shown that RLN3 expression
in the NI and RXFP3 expression in the PVN and SON are elevated
in BE female rats, indicating the involvement of RLN3 actions in
the nonhomeostatic intake of HPF. The PVN and SON constitute
the major source of OXT and AVP, two potent anorexigenic pep-
tides (Meyer et al., 1989; Arletti et al., 1990; Pei et al., 2014;
Yoshimura et al., 2017), with OXT being strongly linked to regula-
tion of sweet and palatable food intake (Leng and Sabatier, 2017).
Hence, the robust inhibitory action of RXFP3 activation on the ac-
tivity of OXT and AVPMNCs in PVN documented here and else-
where (Kania et al., 2017), together with the reduced PVN c-fos
mRNA levels observed in BE females (Lenglos et al., 2013) and the
RXFP3 activation-dependent reduction of OXT and AVP mRNA
expression (Ganella et al., 2013a), point to strong inhibition of
PVN OXT and AVP signaling during BE episodes. Therefore,
future research should aim to determine the specific role of
RXFP3-expressing subpopulations of PVN cells (magnocellular vs
parvocellular and OXT- vs AVP-synthesizing neurons) in the
occurrence and time course of BE behavior.
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The PVN is a hub of central homeostatic control, modulating
hormonal release and autonomic responses. Current data, to-
gether with previous reports (McGowan et al., 2005; Ganella et
al., 2013a; Lenglos et al., 2013; Calvez et al., 2015, 2016b; Kania et
al., 2017; de Ávila et al., 2018) provide extensive evidence that
RLN3/RXFP3 signaling in the PVN constitutes a novel addition
to our understanding of the neural circuitry governing physio-
logical food intake, as well as abnormal eating behavior.
Moreover, as OXT- and AVP-synthesizing MNCs control funda-
mental biological processes, including water balance, reproduc-
tion, nociception, and a variety of social and parenting behaviors
(for review, see Gimpl and Fahrenholz, 2001; Koshimizu et al.,
2012), a direct inhibitory action of RLN3 on these neurons has
broad behavioral implications. Notably, RLN3-synthesizing neu-
rons are highly stress-responsive (Tanaka et al., 2005; Ma et al.,
2013), which together with sex differences in RLN3 actions (for
review, see Calvez et al., 2017) and the involvement of RXFP3 in
BE behavior modulation shown here, provide a strong rationale
for investigating the role of RLN3/RXFP3 signaling in the devel-
opment of stress-related psychiatric conditions (Kumar et al.,
2017), particularly in stress-related eating disorders that differen-
tially affect men and women.
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